Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06680830RecruitingPhase 2
Testing NEU-411 for early Parkinson's with LRRK2 gene change
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
Sun City, ArizonaAges 40–80 - NCT06680037RecruitingPhase 1
Azer-cel therapy for immune-related neurological diseases
This trial is testing an experimental cell therapy called azer-cel for people with certain autoimmune diseases that affect the nervous system. The therapy aims to reduce immune attacks on the body by targeting and removing faulty B cells.
La Jolla, CaliforniaAges 18 years+ - NCT06670638Recruiting
New test for crohn's disease in people with a permanent ileostomy
This study aims to develop a new way to measure inflammation and symptoms in people with Crohn's disease who have a permanent ileostomy. Participants will undergo a routine ileoscopy and answer questions to help create better tools for future clinical trials.
Rochester, MinnesotaAges 18 years+ - NCT05884983Recruiting
Check if special CT and nose scope help screen nasopharyngeal cancer
This study tests whether combining a special CT scan with a nose/throat camera exam (nasopharyngeal endoscopy) can better find nasopharyngeal cancer early. You might benefit if the study shows this approach is accurate and safer for screening.
Zhongshan, GuangdongAges 30–69 - NCT06666413RecruitingPhase 4
Study of Nexviazyme in children with infantile Pompe disease
This study tests the safety and effects of the enzyme replacement therapy avalglucosidase alfa (Nexviazyme) in children with infantile-onset Pompe disease. It is for children who have had Pompe symptoms since infancy and heart problems at diagnosis.
ShanghaiAges Up to 17 years - NCT06669247RecruitingPhase 1/Phase 2
Study of REGN7945 plus linvoseltamab for relapsed or refractory multiple myeloma
This study tests a new combination of two drugs (REGN7945 and linvoseltamab) for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if the combination is safe and effective, and it may offer a new option if other therapies have stopped working.
Sydney, New South WalesAges 18 years+ - NCT06668181RecruitingPhase 3
Study of bimekizumab for kids with certain types of juvenile arthritis
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
CalgaryAges 2–18 - NCT06663137RecruitingPhase 2
Study of a new treatment for high-grade bladder cancer
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
RaananaAges 18–80 - NCT06663332RecruitingPhase 3
Long-term study of guselkumab in children who previously took it
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
Atlanta, GeorgiaAges 3 years+ - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06657144RecruitingPhase 1
Study of CHS-114 and toripalimab for advanced solid tumors
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
Tucson, ArizonaAges 18 years+ - NCT06657378Recruiting
Safety study of Fycompa injection for certain seizures
This study looks at the safety of Fycompa given as an injection for people with partial-onset seizures (seizures that start in one part of the brain) or primary generalized tonic-clonic seizures (seizures that affect both sides of the brain from the start). It includes anyone receiving Fycompa injection for the first time in everyday medical care.
TokyoAges 4 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT06665165RecruitingPhase 1
Study of AMX0114 for people with ALS
This study tests an experimental drug called AMX0114 for people recently diagnosed with ALS. It is an early-phase trial to see if the drug is safe and how it affects the body.
La Jolla, CaliforniaAges 18 years+ - NCT06666491RecruitingPhase 3
Comparing two malaria treatments for P. vivax in people 2 and older
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
AhmedabadAges 2–64 - NCT06659341RecruitingPhase 1
Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Albury, New South WalesAges 18 years+ - NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT06655883RecruitingPhase 3
Testing suvorexant for insomnia in people with opioid use disorder
This study tests whether the sleep medication suvorexant (Belsomra) can help people with opioid use disorder who also have trouble sleeping. If you are stable on medication for opioid use disorder and have not used opioids in the last month, this trial may be an option for you.
Garden Grove, CaliforniaAges 18–70 - NCT06655324RecruitingPhase 1
Safety study of two EBV vaccines in healthy people
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
Glendale, CaliforniaAges 12–30 - NCT06656390RecruitingPhase 1/Phase 2
Testing ALK201 for advanced solid tumors
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Denver, ColoradoAges 18–75 - NCT06651281RecruitingPhase 3
Long-term safety and effectiveness of tulisokibart for Crohn's or colitis
This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.
Bristol, ConnecticutAges Any age - NCT06646276RecruitingPhase 3
New drug combo vs standard care for first-line extensive-stage small cell lung cancer
This trial tests a new combination of drugs (BMS-986489 with chemotherapy) against the current standard treatment (atezolizumab with chemotherapy) for people who have just been diagnosed with extensive-stage small cell lung cancer. It aims to see which approach works better and is safer.
Daphne, AlabamaAges 18 years+ - NCT06652633RecruitingPhase 3
Long-term follow-up of Galapagos CAR T-cell therapy recipients
This study is for people who have already received a specific type of cell therapy (CAR T-cell therapy) made by Galapagos. It will follow them over the long term to see how they are doing.
Boston, MassachusettsAges 18 years+ - NCT06632600RecruitingPhase 2
Study of LXE408 for people with chronic Chagas disease
This trial tests a new drug called LXE408 for people with chronic Chagas disease. It aims to see if the drug is safe and effective, and participants will also receive standard treatment with benznidazole.
Sylmar, CaliforniaAges 18–60
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.